Trial Profile

An Expanded Access Program of Onvansertib in Combination With FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients With KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Onvansertib (Primary)
Indications Colorectal cancer
Focus Expanded access; Therapeutic Use
Sponsors Cardiff Oncology

Most Recent Events

12 Sep 2022 Results presented in a Cardiff Oncology Media Release.
12 Sep 2022 According to a Cardiff Oncology media release, data presented at the European Society for Medical Oncology (ESMO) Congress 2022.
06 Sep 2022 According to a Cardiff Oncology media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com